ADCYAP1 and autoimmune thrombocytopenic purpura: Our experiments again demonstrate that VIP/PACAP is an important part of ITP pathogenesis, and targeted therapy targeting VIP/PACAP-mediated intestinal immune function may become a new research direction for ITP treatment in the near future.